1266784-18-2

Usage

General Description

2-AMINO-2-(5-BROMO-2-FLUOROPHENYL)PROPIONIC ACID METHYL ESTER is a chemical compound that belongs to the class of organic compounds known as phenylpropanoic acids. It is a methyl ester derivative of 2-amino-2-(5-bromo-2-fluorophenyl)propionic acid. 2-AMINO-2-(5-BROMO-2-FLUOROPHENYL)PROPIONIC ACID METHYL ESTER has potential biological activity and may be used in the development of pharmaceutical drugs. It is important to handle and use 2-AMINO-2-(5-BROMO-2-FLUOROPHENYL)PROPIONIC ACID METHYL ESTER with care as it may have potential health hazards if not properly handled.

Upstream product

• 1266784-23-9 (RS)-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionic acid 
• 67-56-1 methanol 
• 1374765-83-9 2-amino-2-(5-bromo-2-fluorophenyl)propanoic acid hydrochloride 
• 1350523-51-1 rac-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionitrile 
• 1266784-17-1 (RS)-5-(5-bromo-2-fluorophenyl)-5-methyl-imidazolidine-2,4-dione 
• 910912-20-8 5-bromo-2-fluoro-N-methoxy-N-methylbenzamide 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 146328-85-0 5-bromo-2-fluoro-benzoic acid 

Downstream Products

• 1266784-13-7 rac-5-(5-bromo-2-fluorophenyl)-5-methylmorpholin-3-one 
• 1266784-24-0 (RS)-2-amino-2-(5-bromo-2-fluoro-phenyl)-propan-1-ol 
• 1266784-31-9 (RS)-5-[5-(benzhydrylidene-amino)-2-fluoro-phenyl]-5-methyl-morpholin-3-one 
• 1266784-38-6 (R)-(+)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide 
• 1266784-40-0 (S)-(-)-N-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-2-chloro-acetamide 
• 1266785-76-5 N-[(RS)-1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-3-phenyl-acrylamide 
• 1266785-74-3 (2RS)-bromo-N-[(RS)-1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-3-phenyl-propionamide 
• 1313525-72-2 3-(5-bromo-2-fluorophenyl)-1,3-dimethylpiperazine-2,5-dione 
• 1313525-73-3 3-(5-bromo-2-fluorophenyl)-1,3-dimethyl-5-thioxopiperazin-2-one 
• 1313525-74-4 5-amino-3-(5-bromo-2-fluorophenyl)-1,3-dimethyl-3,6-dihydro-1H-pyrazin-2-one 
• 1313525-75-5 [6-(5-bromo-2-fluorophenyl)-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl]carbamic acid tert-butyl ester 
• 1313525-76-6 [6-(5-amino-2-fluorophenyl)-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl]carbamic acid tert-butyl ester 
• 1313525-77-7 (6-{5-[(5-bromopyridine-2-carbonyl)amino]-2-fluorophenyl}-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)carbamic acid tert-butyl ester 
• 1313525-28-8 5-bromopyridine-2-carboxylic acid [3-(6-amino-2,4-dimethyl-3-oxo-2,3,4,5-tetrahydropyrazin-2-yl)-4-fluorophenyl]amide 

Relevant academic research and scientific papers

1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads

1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays. We describe lead optimization focused on reducing the amidine pKa while optimizing interactions in the BACE1 active site. Our strategy permi

5-ARYL-1-IMINO-1-OXO-[1,2,4]THIADIAZINES

The present invention provides a compound of formula I' having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

5-AMINO[1,4]THIAZINES AS BACE 1 INHIBITORS

The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.

3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER FORMS OF DEMENTIA

The present invention relates to novel 3-amino-5,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical com

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides 1,4 Oxazines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazines of formula I having BACE 1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the prese

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

1,4 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention relates to 1,4 Oxazines of formula (I): having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pre

3-AMINO-5,6-DIHYDRO-1H-PYRAZIN-2-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ALZHEIMER?S DISEASE AND OTHER FORMS OF DEMENTIA

The present invention relates to novel 3-amino-5,6-dihydro-1H-pyrazin-2-one derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical com